In Vitro Reversal of the Anti-Aggregant Effect of Ticagrelor Using Untreated Platelets

Thrombosis and Haemostasis

Volumn 118, Issue 11, 2018, Pages 1895-1901

  Kruger, Paul C ^a,b   Hirsh, Jack ^c   Bhagirath, Vinai C ^a,c   Xu, Ke ^d   Dale, Brian ^e,f   De Vries, Tim A C ^a   Ginsberg, Jeffrey S ^c   Eikelboom, John W ^a,c,f   Chan, Noel C ^a,c,f  

^a MCMASTER UNIVERSITY   (Canada)

^b FIONA STANLEY HOSPITAL   (Australia)

^c MCMASTER UNIVERSITY   (Canada)

^d NANJING MEDICAL UNIVERSITY   (China)

^e UNIVERSITY OF SOUTH AUSTRALIA   (Australia)

^f MCMASTER UNIVERSITY   (Canada)

Author keywords

aggregation; aspirin; platelet transfusion; ticagrelor

Indexed keywords

ACETYLSALICYLIC ACID; ADENOSINE DIPHOSPHATE; ARACHIDONIC ACID; TICAGRELOR; ANTITHROMBOCYTIC AGENT;

ACUTE CORONARY SYNDROME; ADULT; ARTICLE; BLEEDING; CAROTID ARTERY STENTING; FEMALE; HUMAN; LIGHT TRANSMISSION AGGREGOMETRY; MALE; MEDICAL PROCEDURES; NORMAL HUMAN; PLATELET COUNT; PRIORITY JOURNAL; THROMBOCYTE AGGREGATION; THROMBOCYTE FUNCTION; THROMBOCYTE RICH PLASMA; THROMBOCYTE TRANSFUSION; CELL CULTURE; CLINICAL TRIAL; DRUG EFFECT; METABOLISM; PHYSIOLOGY; RISK; THROMBOCYTE; THROMBOSIS; YOUNG ADULT;

ACUTE CORONARY SYNDROME; ADENOSINE DIPHOSPHATE; ADULT; BLOOD PLATELETS; CELLS, CULTURED; FEMALE; HEALTHY VOLUNTEERS; HEMORRHAGE; HUMANS; MALE; PLATELET AGGREGATION; PLATELET AGGREGATION INHIBITORS; PLATELET TRANSFUSION; PLATELET-RICH PLASMA; RISK; THROMBOSIS; TICAGRELOR; YOUNG ADULT;

EID: 85055607672     PISSN: 03406245     EISSN: None     Source Type: Journal    
DOI: 10.1055/s-0038-1673381     Document Type: Article

References (30)

1. Wallentin L. Becker R. C. Budaj A., et al. PLATO Investigators. Ticagrelor versus clopidogrel in patients with acute coronary syndromes. N Engl J Med: 2009; 361 11 1045 1057
2. Reaume K. T. Regal R. E. Dorsch M. P. Indications for dual antiplatelet therapy with aspirin and clopidogrel: evidence-based recommendations for use. Ann Pharmacother: 2008; 42 04 550 557
3. Niitsu Y. Jakubowski J. A. Sugidachi A. Asai F. Pharmacology of CS-747 (prasugrel, LY640315), a novel, potent antiplatelet agent with in vivo P2Y12 receptor antagonist activity. Semin Thromb Hemost: 2005; 31 02 184 194
4. Li C. Hirsh J. Xie C. Johnston M. A. Eikelboom J. W. Reversal of the anti-platelet effects of aspirin and clopidogrel. J Thromb Haemost: 2012; 10 04 521 528
5. Sharma S. Bhambi B. Use of platelet transfusion to facilitate surgery in patients on clopidogrel and aspirin therapy after drug-eluting stent percutaneous coronary intervention. Catheter Cardiovasc Interv: 2012; 79 03 498
6. Hansson E. C. Shams Hakimi C. Åström-Olsson K., et al. Effects of ex vivo platelet supplementation on platelet aggregability in blood samples from patients treated with acetylsalicylic acid, clopidogrel, or ticagrelor. Br J Anaesth: 2014; 112 03 570 575
7. Bonhomme F. Bonvini R. Reny J. L. Poncet A. Fontana P. Impact of non-inhibited platelet supplementation on platelet reactivity in patients treated with prasugrel or ticagrelor for an acute coronary syndrome: an ex vivo study. Platelets: 2015; 26 04 324 330
8. Taylor G. Osinski D. Thevenin A. Devys J. M. Is platelet transfusion efficient to restore platelet reactivity in patients who are responders to aspirin and/or clopidogrel before emergency surgery? J Trauma Acute Care Surg: 2013; 74 05 1367 1369
9. Vilahur G. Choi B. G. Zafar M. U., et al. Normalization of platelet reactivity in clopidogrel-treated subjects. J Thromb Haemost: 2007; 5 01 82 90
10. O'Connor S. A. Amour J. Mercadier A., et al. ACTION Study Group. Efficacy of ex vivo autologous and in vivo platelet transfusion in the reversal of P2Y12 inhibition by clopidogrel, prasugrel, and ticagrelor: the APTITUDE study. Circ Cardiovasc Interv: 2015; 8 11 e002786
11. Storey R. F. Angiolillo D. J. Patil S. B., et al. Inhibitory effects of ticagrelor compared with clopidogrel on platelet function in patients with acute coronary syndromes: the PLATO (PLATelet inhibition and patient Outcomes) PLATELET substudy. J Am Coll Cardiol: 2010; 56 18 1456 1462
12. Husted S. van Giezen J. J. Ticagrelor: the first reversibly binding oral P2Y12 receptor antagonist. Cardiovasc Ther: 2009; 27 04 259 274
13. Dobesh P. P. Oestreich J. H. Ticagrelor: pharmacokinetics, pharmacodynamics, clinical efficacy, and safety. Pharmacotherapy: 2014; 34 10 1077 1090
14. Gurbel P. A. Bliden K. P. Butler K., et al. Randomized double-blind assessment of the ONSET and OFFSET of the antiplatelet effects of ticagrelor versus clopidogrel in patients with stable coronary artery disease: the ONSET/OFFSET study. Circulation: 2009; 120 25 2577 2585
15. Buchanan A. Newton P. Pehrsson S., et al. Structural and functional characterization of a specific antidote for ticagrelor. Blood: 2015; 125 22 3484 3490
16. Pehrsson S. Johansson K. J. Janefeldt A., et al. Hemostatic effects of the ticagrelor antidote MEDI2452 in pigs treated with ticagrelor on a background of aspirin. J Thromb Haemost: 2017; 15 06 1213 1222
17. Angheloiu G. O. Gugiu G. B. Ruse C. Pandey R. Dasari R. R. Whatling C. Ticagrelor removal from human blood. JACC Basic Transl Sci: 2017; 2 02 135 145
18. Hobl E. L. Derhaschnig U. Firbas C. Schoergenhofer C. Schwameis M. Jilma B. Reversal strategy in antagonizing the P2Y12 -inhibitor ticagrelor. Eur J Clin Invest: 2013; 43 12 1258 1261
19. Martin A. C. Berndt C. Calmette L., et al. The effectiveness of platelet supplementation for the reversal of ticagrelor-induced inhibition of platelet aggregation: an in-vitro study. Eur J Anaesthesiol: 2016; 33 05 361 367
20. Zafar M. U. Smith D. A. Baber U., et al. Impact of timing on the functional recovery achieved with platelet supplementation after treatment with ticagrelor. Circ Cardiovasc Interv: 2017; 10 08 e005120
21. Hansson E. C. Malm C. J. Hesse C., et al. Platelet function recovery after ticagrelor withdrawal in patients awaiting urgent coronary surgery. Eur J Cardiothorac Surg: 2017; 51 04 633 637
22. Chrono-Par® and Chrono-LUME® reagents for platelet function testing and secretion studies in whole blood and platelet rich plasma (Information leaflet). Chrono-log Corporation, Havertown, PA, United States of America; 2017
23. DiMinno G. Silver M. J. Murphy S. Stored human platelets retain full aggregation potential in response to pairs of aggregating agents. Blood: 1982; 59 03 563 568
24. Teng R. Carlson G. F. Nylander S. Andersson T. L. Effects of autologous platelet transfusion on platelet inhibition in ticagrelor-treated and clopidogrel-treated subjects. J Thromb Haemost: 2016; 14 12 2342 2352
25. Zakko L. Rustagi T. Douglas M. Laine L. No benefit from platelet transfusion for gastrointestinal bleeding in patients taking antiplatelet agents. Clin Gastroenterol Hepatol: 2017; 15 01 46 52
26. Baharoglu M. I. Cordonnier C. Al-Shahi Salman R., et al. PATCH Investigators. Platelet transfusion versus standard care after acute stroke due to spontaneous cerebral haemorrhage associated with antiplatelet therapy (PATCH): a randomised, open-label, phase 3 trial. Lancet: 2016; 387 (10038): 2605 2613
27. Becker R. C. Bassand J. P. Budaj A., et al. Bleeding complications with the P2Y12 receptor antagonists clopidogrel and ticagrelor in the PLATelet inhibition and patient Outcomes (PLATO) trial. Eur Heart J: 2011; 32 23 2933 2944
28. Plicner D. Mazur P. Hymczak H., et al. Preoperative platelet aggregation predicts perioperative blood loss and rethoracotomy for bleeding in patients receiving dual antiplatelet treatment prior to coronary surgery. Thromb Res: 2015; 136 03 519 525
29. McCullough J. Overview of platelet transfusion. Semin Hematol: 2010; 47 03 235 242
30. Murphy S. Heaton W. A. Rebulla P. Platelet production in the Old World - and the New. Transfusion: 1996; 36 08 751 754